Table 3.
Meta-analysis of gene expression affected by oxygen therapy in LOTT and COPDGene
| Gene symbol |
P-value LOTT |
P-value COPDGene |
Combined P-value* |
Adj. Combined P-value*† |
|---|---|---|---|---|
| NDUFA1 | 1.37e-03 | 3.15e-01 | 3.89e-03 | 5.82e-03 |
| NDUFA6 | 4.42e-04 | 1.01e-02 | 6.92e-05 | 3.74e-04 |
| NDUFB3 | 5.87e-03 | 1.92e-02 | 9.41e-04 | 2.31e-03 |
| NDUFS4 | 1.47e-03 | 4.63e-03 | 9.58e-05 | 4.31e-04 |
| COX6C | 2.31e-03 | 2.54e-04 | 1.52e-05 | 2.78e-04 |
| MRPL35 | 4.49e-03 | 1.41e-01 | 4.45e-03 | 5.82e-03 |
| MRPS18C | 3.60e-03 | 1.25e-02 | 4.39e-04 | 1.32e-03 |
| MRPS33 | 9.27e-03 | 1.61e-02 | 1.19e-03 | 2.68e-03 |
| TMEM126A | 8.21e-03 | 4.66e-02 | 2.69e-03 | 4.84e-03 |
| UQCRH | 7.20e-03 | 4.34e-02 | 2.26e-03 | 4.69e-03 |
| FADS2 | 3.23e-03 | 1.07e-01 | 2.60e-03 | 4.84e-03 |
| COQ5 | 3.33e-03 | 7.25e-03 | 2.64e-04 | 8.90e-04 |
| ACSM3 | 4.97e-03 | 6.45e-01 | 3.38e-02 | 3.51e-02 |
| THEM2 | 8.29e-03 | 7.32e-02 | 4.04e-03 | 5.82e-03 |
| GSR | 1.23e-02 | 4.87e-02 | 3.94e-03 | 5.82e-03 |
| LSM1 | 5.84e-03 | 2.53e-04 | 2.99e-05 | 2.78e-04 |
| LSM3 | 5.09e-03 | 1.06e-02 | 5.09e-04 | 1.38e-03 |
| LSM7 | 7.24e-03 | 9.26e-02 | 4.47e-03 | 5.82e-03 |
| NSA2 | 9.86e-03 | 1.57e-01 | 9.53e-03 | 1.07e-02 |
| RPL26L1 | 7.23e-03 | 1.47e-01 | 6.92e-03 | 8.12e-03 |
| RPL26 | 3.84e-03 | 1.02e-03 | 6.23e-05 | 3.74e-04 |
| RPL31 | 8.91e-03 | 1.27e-03 | 1.43e-04 | 5.53e-04 |
| RPL34 | 2.70e-03 | 5.74e-04 | 3.09e-05 | 2.78e-04 |
| RPS17 | 7.25e-03 | 8.00e-01 | 7.95e-02 | 7.95e-02 |
| SRP14 | 9.88e-03 | 7.04e-02 | 4.53e-03 | 5.82e-03 |
| ZCCHC17 | 9.80e-03 | 8.47e-02 | 5.32e-03 | 6.53e-03 |
| ARSB | 2.04e-01 | 3.07e-02 | 3.10e-02 | 3.35e-02 |
Significant result at 5% significance level is shown in bold.
*
Combined P-values using weighted Z-method
†
Adjusted P-values using Benjamini and Hochberg’s method